Introduction
Following the discovery of hepatitis C virus (HCV) as the major cause of non-A, non-B hepatitis (1) , most cases with chronic liver disease, including chronic hepatitis , liver cirrhosis and hepatocellular carcinoma (HCC), were found to be caused by hepatitis B virus (HBV) or HCV infection, including cases reported in Nagasaki Prefecture (2) , where the HBVcarrier rate is higher than in other parts of Japan (3) . Although reliable immunoassays and molecular probes for detecting HBVand HCVare currently available (4, 5) , it is still difficult to completely rule out the presence of HBVand HCV infections. Moreover, 10-20% of non-A, non-B hepatitis cases are causedby non-C, non-E etiologic agent(s) (6) whichhas (have)remained to be clarified. Kodali et al (7) also reported that the underlying mechanism of approximately 5 % of patients with chronic hepatitis/cirrhosis is unknown despite the use of HCV-RNA testing. Therefore, yet unidentifiednon-B, non-C agent(s) might be implicated in chronic liverdisease (8) . Butthe natural courseof non-B, non-C chronic liver disease has been seldom described.
In the present study,we examined the clinical manifestations of patients diagnosed with hepatitis B surface antigen (HBsAg) and antibody to the hepatitis C virus (anti-HCV) negative chronic liver disease in Nagasaki Prefecture, Japan. We also compared their features with those reported for type B and type C chronic liver disease.
Patients and Methods
A total of 40 patients with HBsAgand anti-HCV negative chronic hepatitis, liver cirrhosis or HCC,including 25 females and 15 males (range: 12-88 years, mean, 60 years), were registered between April 1974 and October 1993 in the Nagasaki Hepatitis Study Group according to the following criteria:
1) The patient exhibited elevated levels of serum aminotransferases, and was followed for at least 6 months.
2) The patient was seronegative for HBsAg,and for anti-HCV confirmed by enzyme immunoassay or radioimmunoassay (second generation).
3) Patients with high titres of antibody to the hepatitis B core antigen (anti-HBc) were excluded from the study. 4) The diagnosis of chronic hepatitis and liver cirrhosis was based on histologic and/or peritoneoscopic findings, while the diagnosis of HCCwas based on histological and/or angiographic examination. 5) Patients with drug-induced liver injury, those with a history of chronic alcohol consumption (>70 g/day for 5 years or more), patients with fatty liver diagnosed by characteristic findings on ultrasonography and/or computed tomography, and patients with autoimmune hepatitis or primary biliary cirrhosis were also excluded from the present study.
The activity pattern of alanine aminotransferase (ALT) during the follow-up period was classified into 6 types, shown schematically in Fig. 1 . Type 1 was characterized by the presence of normal or slightly elevated levels of ALT(less than twice the upper normal limit) throughout the follow-up period. Type 2 showed fluctuating high levels of ALTactivity in the initial phase of the disease with subsequent return to a normal level. Type 3 represented abnormally high levels of ALT(less than three times the upper normal limit) throughout the followup period. Type 4 was similar to type 3 but the level ofALT was persistently less than five times the upper normal limit. Type 5 represented abnormally high levels of ALT(more than five times the upper normal limit) throughout the follow-up period. Finally, type 6 was characterized by fluctuating levels of ALT activity with the low levels approaching normal values while the high levels exceeded three times the upper normal limit.
The observation period commencedwith enrolment and all patients were followed regularly at participating hospitals; the study period was terminated at the end of April 1994. Of the 40 patients, 4 were lost to follow-up and 4 died during the study.
Values were expressed as mean±SD. Statistical analysis was performed using the chi-square test or Fisher's exact probability test (two-tailed). A p value of less than 0.05 was considered significant. patients (13%) had received blood transfusions in the past and 7 (18%) gave a family history of liver diseases. Of these 40 patients, 2 patients had a history of angina pectoris, 6 diabetes mellitus, 7 hypertension, 3 gall stones, 1 duodenal ulcer and 1 patient had chronic thyroiditis.
AL T activity patterns
Of these 40 patients, 9 (22.5%) patients showed an ALT profile of type 1, 6 (15%) showedtype 2, 12 (30%) showedtype 3, 6 (15%) showed type 4, 7 (17.5%) showed type 6, and no patient showed type 5 ( Fig. 1 ).
Long-term outcome
The long-term outcome for 34 patients is shown in Fig. 2 Incidence of hepatocellular carcinoma During the follow-up period, HCCwas recognized in 9 of34 (26.5%) patients, based on histological and/or angiographic findings. Of these 9 cases, 5 were initially diagnosed with liver cirrhosis, 3 with chronic active hepatitis, and 1 with chronic persistent hepatitis. Therefore, the incidence of HCCwas 55.6% (5 of9) in liver cirrhosis and 18.2% (4 of22) in chronic hepatitis. In our population sample, the yearly incidence of background of these 9 patients who developed HCCis summarized in Table 3 .
The positivity rate of anti-HBs and anti-HBc in all patients testedandinpatients whodevelopedHCC was 39.3% (1 1 of28) and 41.2% (7 of 17), 57.1% (4 of7) and 42.9% (3 of7) respectively. There was no correlation, in general, between seropositivity of anti-HBs or anti-HBc and the likelihood of developing HCC.
Discussion
The criteria selected for enrolment in the present study did not exclude the presence of HBVor HCVinfection since the detection of serum HBV-DNA or HCV-RNAby PCR technique was not performed. Uchida et al (9) reported that the PCR successfully amplified serum HBV-DNAs in 85% of non-B, non-C, non-D chronic hepatitis. De Mitri et al ( 1 0) also analyzed liver tissues and serum samples from 19 patients negative for
HBsAg by PCR. Their results demonstrated that 13 and 7
patients were HCV-RNAand HBV-DNApositive in liver tissue, respectively. Moreover, several reports have recently provided evidence for other agents of humannon-A, non-B, non-C, non-D, non-E hepatitis (6, 1 1, 12) . Therefore, it is likely that our population sample contained a numberof patients with type B, type C or other etiologic agent(s). However, since it is still difficult to rule out these cases entirely even after the use of the PCR technique, it is important to examine the clinical manifestations of cases diagnosed with non-B, non-C chronic liver disease based on conventional serological markers of HBVand HCV. Of the 40 patients, 27 (67.5 %) exhibited ALT profiles of type 1 , 2 or 3, representing a mild ALT activity. These ALTprofiles were milder than those of type C chronic liver disease (13, 14) , Table 2 . Relationship between ALT Activity Pattern and Incidence of HCC *p=0. 1 880 (two-tailed Fisher's exact probability test). ALT: alanine aminotransferase, HCC:hepatocellular carcinoma. (15) . While some patients showed a rapid progression, there was no correlation, in general, between the ALTprofile and the long-term outcome. Wepreviously reported the risk ofHCCin patients with liver cirrhosis in Nagasaki Prefecture (16) , the cumulative risk of HCCin non-B , non-C cirrhotic patients was significantly lower than that in type B or type C groups. In the present study, however, the yearly incidence ofHCC was 9.7% in HBsAgand anti-HCV negative cirrhotic patients, which was higher than that reported previously (16) . This high incidence may be influenced by the presence of HBVor HCVinfection in our patients, since 6 (66.7%) of the 9 patients who developed HCC were suspected to have been exposed in the pastto HBVorHCV (Table 3) . Interestingly, 5 of the 7 tested patients were seropositive for anti-HBs and/or anti-HBc, suggesting that these patients were infected in the past by HBV. HCCmay develop after inactivation of HBVreplication in HBVcarrier patients. HBV carrier state has somedirect influence on hepatocarcinogenesis , because the integration of HBVhas been detected in almost all patients with HCC, mainly attributed to transcriptional transactivating activity of the X gene (17) . Although we did not test for HBV-DNA in our patients, it is likely that the high incidence of development of HCCwas, in part, attributed to HBV.
In conclusion, the ALTactivity pattern and long-term progression of HBsAgand anti-HCV negative chronic liver disease were milder than those of type B or type C chronic liver diseases. However, the clinical course in a number of patients was similar to that of type B or type C chronic liver disease, including a high incidence of HCC (18) (19) (20) . Our findings indicate that more detailed and accurate tests for detecting HBV and HCV, e.g., combined one-step PCRmethod to detect both HCV-RNA and HBV-DNA in a single serum specimen (21) , should be considered before making the diagnosis of non-B, non-C chronic liver disease.
